Dataset Information

Butyrate deficiency due to microbial dysbiosis promotes anxiety

ABSTRACT:

for this association remains incompletely understood. Diabetes-associated genes have been implicated in the control of central nervous system (CNS) disorders. In the current study, we observed a significant downregulation of secretagogin (SCGN) across multiple organs in diabetic mouse models. Consequently, SCGN knockout (Scgn-/-) mice developed diabetes, confirming SCGN as a diabetes-associated gene. Behavioral analyses revealed that Scgn-/- mice exhibited anxiety-like phenotypes compared to wild-type (WT) mice. Notably, germ-free (GF) Scgn-/- mice did not manifest these behavioral abnormalities, demonstrating that SCGN influences anxiety through gut microbiota-dependent mechanisms. Subsequent 16S rRNA sequencing confirmed gut microbiota dysbiosis in Scgn-/- mice. Fecal microbiota transplantation (FMT) from Scgn-/- donors into GF mice recapitulated the anxiety-like phenotypes. Given the established roles of microbial metabolites in gut-brain axis signaling, we quantified short-chain fatty acids (SCFAs), identifying marked depletion of a key neuroactive metabolite, butyrate, in the Scgn-/- fecal and plasma samples. Immunohistochemical analysis revealed neural overactivation via c-Fos expression in the medial prefrontal cortex (mPFC) of Scgn-/- mice, which was corroborated by metabolomic profiling indicating dysregulated tryptophan metabolism in this region. Mechanistically, the upregulation of indoleamine 2,3-dioxygenase 1 (IDO1) and kynureninase (KYNU) promoted excessive quinolinic acid production. This NMDA receptor agonist enhanced pyramidal neuron excitability in the mPFC, driving anxiety-like behaviors in Scgn-/- mice. Critically, butyrate administration reversed this pathological cascade in vivo and in vitro, as validated by electrophysiological recordings. Taken together, our findings demonstrate that SCGN deficiency induces gut dysbiosis, reduces butyrate bioavailability, and promotes mPFC excitotoxicity through disrupted tryptophan metabolism, ultimately culminating in anxiety. This SCGN-modulated gut-brain axis identifies novel therapeutic targets for diabetes-associated anxiety.

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse-phase, Liquid Chromatography MS - positive - reverse-phase

PROVIDER: MTBLS13477 | MetaboLights | 2026-03-01

REPOSITORIES: MetaboLights

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	a_MTBLS13477_LC-MS_negative_reverse-phase_metabolite_profiling.txt	Txt
	a_MTBLS13477_LC-MS_positive_reverse-phase_metabolite_profiling.txt	Txt
	i_Investigation.txt	Txt
	m_MTBLS13477_LC-MS_negative_reverse-phase_metabolite_profiling_v2_maf.tsv	Tabular
	m_MTBLS13477_LC-MS_positive_reverse-phase_metabolite_profiling_v2_maf.tsv	Tabular

Items per page:

1 - 5 of 6

Similar Datasets

Project description:Chronic diseases arise when pathophysiological processes achieve a steady state by self-reinforcing. Here, we explored the possibility of a self-reinforcement state in a common condition, chronic constipation, where alterations of the gut microbiota have been reported. The functional impact of the microbiota shifts on host physiology remains unclear, however we hypothesized that microbial communities adapted to slow gastrointestinal transit affect host functions in a way that reinforces altered transit, thereby maintaining the advantage for microbial self-selection. To test this, we examined the impact of pharmacologically (loperamide)-induced constipation (PIC) on the structural and functional profile of altered gut microbiota. PIC promoted changes in the gut microbiome, characterized by decreased representation of butyrate-producing Clostridiales, decreased cecal butyrate concentration and altered metabolic profiles of gut microbiota. PIC-associated gut microbiota also impacted colonic gene expression, suggesting this might be a basis for decreased gastrointestinal (GI) motor function. Introduction of PIC-associated cecal microbiota into germ-free (GF) mice significantly decreased GI transit time. Our findings therefore support the concept that chronic diseases like constipation are caused by disease-associated steady states, in this case, caused by reciprocating reinforcement of pathophysiological factors in host-microbe interactions. We used microarrays to detail the global gene expression profile in the proximal colon smooth muscle tissues of germ-free, conventionalized, or specific pathogen free mouse C57Bl/6 female and male specific pathogen free (SPF) mice were bred and housed in the animal care facility at the University of Chicago. Mice of 8–10 weeks of age were treated with 0.1% loperamide in the drinking water for 7 days. Age matched, germ-free (GF) C57Bl/6 mice were gavaged orally with cecal luminal contents harvested from control or loperamide-treated C57Bl/6 donor mice. Recipient mice were sacrificed 4 weeks post-colonization.

Project description:Pancreatic cancer is the 3rd most prevalent cause of cancer related deaths in United states alone, with over 55000 patients being diagnosed in 2019 alone and nearly as many succumbing to it. Late detection, lack of effective therapy and poor understanding of pancreatic cancer systemically contributes to its poor survival statistics. Obesity and high caloric intake linked co-morbidities like type 2 diabetes (T2D) have been attributed as being risk factors for a number of cancers including pancreatic cancer. Studies on gut microbiome has shown that lifestyle factors as well as diet has a huge effect on the microbial flora of the gut. Further, modulation of gut microbiome has been seen to contribute to effects of intensive insulin therapy in mice on high fat diet. In another study, abnormal gut microbiota was reported to contribute to development of diabetes in Db/Db mice. Recent studies indicate that microbiome and microbial dysbiosis plays a role in not only the onset of disease but also in its outcome. In colorectal cancer, Fusobacterium has been reported to promote therapy resistance. Certain intra-tumoral bacteria have also been shown to elicit chemo-resistance by metabolizing anti-cancerous agents. In pancreatic cancer, studies on altered gut microbiome have been relatively recent. Microbial dysbiosis has been observed to be associated with pancreatic tumor progression. Modulation of microbiome has been shown to affect response to anti-PD1 therapy in this disease as well. However, most of the studies in pancreatic cancer and microbiome have remained focused om immune modulation. In the current study, we observed that in a T2D mouse model, the microbiome changed significantly as the hyperglycemia developed in these animals. Our results further showed that, tumors implanted in the T2D mice responded poorly to Gemcitabine/Paclitaxel (Gem/Pac) standard of care compared to those in the control group. A metabolomic reconstruction of the WGS of the gut microbiota further revealed that an enrichment of bacterial population involved in drug metabolism in the T2D group.

Dataset Information

Butyrate deficiency due to microbial dysbiosis promotes anxiety

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets